Go Pro
NASDAQ:NKTX

Nkarta Q2 2026 Earnings Report

Nkarta logo
$2.76 -0.19 (-6.44%)
Closing price 04:00 PM Eastern
Extended Trading
$2.76 0.00 (-0.18%)
As of 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nkarta EPS Results

Actual EPS
-$0.54
Consensus EPS
-$0.36
Beat/Miss
Missed by -$0.18
One Year Ago EPS
N/A

Nkarta Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nkarta Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Monday, August 10, 2026
Conference Call Time
4:00PM ET

Upcoming Earnings

Nkarta's Q3 2026 earnings is estimated for Tuesday, November 10, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Nkarta Earnings Headlines

Nkarta to Participate in September Investor Conferences
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Nkarta (NKTX) Stock Forecast & Price Target
See More Nkarta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nkarta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nkarta and other key companies, straight to your email.

About Nkarta

Nkarta (NASDAQ:NKTX) is a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies for the treatment of cancer. The company’s approach is designed to use allogeneic, or donor-derived, immune cells that can be manufactured for use across multiple patients, with the goal of providing an off-the-shelf alternative to individualized cell therapies.

Nkarta’s product candidates include NKX101, an engineered CAR NK cell therapy designed to recognize NKG2D ligands expressed on certain cancer cells, and NKX019, a CD19-targeted CAR NK cell therapy being developed for B-cell malignancies. The company has evaluated these programs in clinical studies involving conditions such as acute myeloid leukemia, myelodysplastic syndromes and B-cell cancers.

Founded in 2015 and headquartered in San Francisco, California, Nkarta focuses primarily on research and clinical development rather than commercialized products. Its activities are centered on advancing its cell therapy pipeline through clinical testing and regulatory development. The company’s therapies are investigational and have not been approved for commercial use.

View Nkarta Profile